NCT06647134Recruiting
A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy
M.D. Anderson Cancer Center
Start Date
9/11/2024
Completion Date
3/31/2028
Summary
To understand the severity and nature of participants experiences during irAEs following immune checkpoint inhibitor immunotherapy.
Detailed Description
1. To understand the severity and nature of participants experiences during rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, including their functional impact 2. To explore domains relevant to participants experiencing rheumatic immune-related adverse events following immune checkpoint inhibitor immunotherapy, and attitudes to domains identified from the literature
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria
The criteria are:
* Patients aged 18 years and above
* English (conversational level) speaking, with the ability to give informed consent
* Patients with a rheumatologist clinician diagnosis of inflammatory arthritis irAE or PMR irAE following ICI therapy
Exclusion Criteria
* Acutely life-threatening or worsening cancer
* Hearing impairment functionally limiting participation in verbal interview
Conditions
ArthritisPolymyalgia RheumaticaImmune Checkpoint Inhibitors
Locations
MD Anderson Cancer Center
Houston, Texas 77030
United States